Hepatitis C News and Research

Latest Hepatitis C News and Research

Debiopharm Group signs exclusive licence agreement with Novartis for alisporivir

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan.

9 Feb 2010

Two U.S. insurers approve coverage of radioembolization for treatment of unresectable liver cancer

MDS Nordion, a global leader in providing products and services for medical imaging and radiotherapeutics, today announced that two of the largest health insurers in the United States have recently approved coverage of radioembolization to treat unresectable liver cancer, which includes the use of MDS Nordion's TheraSphere(R) treatment. The two insurance companies and their affiliates together serve more than one-quarter of Americans and do business in all 50 states.

6 Feb 2010

Biota Holdings reports Relenza sales, indicative royalties for three months ended 31 December 2009

Biota Holdings Limited today announced that it had received written notification from GlaxoSmithKline that Relenza sales were $462 million and indicative royalties were $32.6 million, for the three months ended 31 December 2009.

5 Feb 2010

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.

4 Feb 2010

Global cancer rates could be reduced by 40% with prevention strategies, report says

"Forty percent of the 12 million people diagnosed with cancer worldwide each year could avert the killer disease by protecting themselves against infections and changing their lifestyles, experts said on Tuesday," Reuters reports.

4 Feb 2010

Closing funding gap for federal viral hepatitis education, screening and surveillance programs stops liver cancer

With most liver cancer caused by undetected or untreated hepatitis B or C viral infection, the 22,000 new cases of liver cancer that are diagnosed each year could be dramatically reduced if Congress took decisive action to close the funding gap for federal viral hepatitis education, screening, and surveillance programs, the National Viral Hepatitis Roundtable (NVHR) said today.

4 Feb 2010

RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation

ZymoGenetics, Inc., today announced the publication of pooled safety and immunogenicity observations from eight clinical trials of RECOTHROM in the February issue of the Journal of the American College of Surgeons. The authors concluded that RECOTHROM is a well-tolerated topical hemostatic agent in numerous surgical settings and has a low rate of anti-product antibody formation. In the pooled data from all trials, less than one percent of treated patients developed product-specific antibodies. None of the antibodies neutralized native coagulation proteins.

2 Feb 2010

Study shows antiviral drugs could offer protection against HIV, Ebola, herpes and hepatitis C

The development of antibiotics gave physicians seemingly miraculous weapons against infectious disease. Effective cures for terrible afflictions like pneumonia, syphilis and tuberculosis were suddenly at hand. Moreover, many of the drugs that made them possible were versatile enough to knock out a wide range of deadly bacterial threats.

2 Feb 2010

Researchers identify antiviral small molecule that is effective against numerous viruses

Viruses are insidious creatures. They differ from each other in many ways, and they can mutate - at times seemingly at will, as with HIV - to resist a host of weapons fired at them. Complicating matters further is that new viruses are constantly emerging.

2 Feb 2010

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Romark Laboratories announced that it has initiated enrollment of patients in a clinical trial of Alinia® (nitazoxanide) for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain.

1 Feb 2010

Pharmasset exercises option to purchase additional shares

Pharmasset, Inc. announced today the underwriter of its recent stock offering has exercised its option to purchase an additional 230,400 shares of common stock.

30 Jan 2010

U.S. Marshals seize unapproved ozone generators from Applied Ozone Systems

At the request of the U.S. Food and Drug Administration, U.S. Marshals today seized 79 ozone generators, models AOS-1M and AOS-1MD, from Applied Ozone Systems of Auburn, Calif. The seized goods, which are medical devices, are valued at $75,900.

30 Jan 2010

Experimental vaccine protects mice and monkeys against chikungunya virus

An experimental vaccine developed using non-infectious virus-like particles (VLP) has protected macaques and mice against chikungunya virus, a mosquito-borne pathogen that has infected millions of people in Africa and Asia and causes debilitating pain, researchers at the National Institutes of Health have found.

29 Jan 2010

Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV

Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients. Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy.

28 Jan 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010

NewsRx publishes new encyclopedia on vaccines

NewsRx, a 25-year-old publisher and international news organization headquartered in Atlanta, has published a new encyclopedia on vaccines -- Encyclopedia of Vaccines, 2009: An encyK Resource for Parents, Patients & Professionals.

28 Jan 2010

Patients with NAFLD have higher overall mortality rate, say researchers

Researchers from the Karolinska Institute determined that patients with nonalcoholic fatty liver disease (NAFLD) have a higher overall mortality rate compared with the general population.

28 Jan 2010

Budgetary freeze will impact over 5M Americans afflicted with chronic viral hepatitis

Ms. Lorren Sandt, Chair of the National Viral Hepatitis Roundtable (NVHR) issued the following statement in advance of the President's State of the Union Address. NVHR is a coalition of more than 150 public, private, and voluntary organizations dedicated to reducing the incidence of infection, morbidity, and mortality from chronic viral hepatitis that afflicts more than 5 million Americans:

28 Jan 2010

Abbott declares quarterly dividend of 40 cents per share

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2009.

27 Jan 2010

TE can be accurately performed in majority of NAFLD patients to exclude advanced fibrosis

Researchers from France and Hong Kong determined that transient elastography (TE), a noninvasive, ultrasonic imaging modality, can be accurately performed in the majority of patients with nonalcoholic fatty liver disease (NAFLD) to exclude advanced fibrosis. Full findings of this study, funded by the Chinese University of Hong Kong, appear in the February issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

27 Jan 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Debiopharm Group signs exclusive licence agreement with Novartis for alisporivir

Two U.S. insurers approve coverage of radioembolization for treatment of unresectable liver cancer

Biota Holdings reports Relenza sales, indicative royalties for three months ended 31 December 2009

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Global cancer rates could be reduced by 40% with prevention strategies, report says

Closing funding gap for federal viral hepatitis education, screening and surveillance programs stops liver cancer

RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation

Study shows antiviral drugs could offer protection against HIV, Ebola, herpes and hepatitis C

Researchers identify antiviral small molecule that is effective against numerous viruses

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Pharmasset exercises option to purchase additional shares

U.S. Marshals seize unapproved ozone generators from Applied Ozone Systems

Experimental vaccine protects mice and monkeys against chikungunya virus

Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV

Ligand Pharmaceuticals acquires Metabasis Therapeutics

NewsRx publishes new encyclopedia on vaccines

Patients with NAFLD have higher overall mortality rate, say researchers

Budgetary freeze will impact over 5M Americans afflicted with chronic viral hepatitis

Abbott declares quarterly dividend of 40 cents per share

TE can be accurately performed in majority of NAFLD patients to exclude advanced fibrosis

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in